Spero Therapeutics Hosting Key Opinion Leader Call on Oral Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections - Seite 2

In addition to his clinical work, Dr. Kaye’s research interests include the development of antimicrobial resistance, particularly among gram-negative organisms; prevention of healthcare associated infections; management of hospital-acquired infections in the elderly; and innovative approaches to antimicrobial stewardship. He has a long and consistent record of federal funding for research pertaining to management and prevention of multi-drug resistant organisms and healthcare-associated infections, including groundbreaking clinical trials.

Dr. Kaye received his medical degree from the University of Pennsylvania and completed his Internal Medicine residency and Infectious Diseases fellowship at Beth Israel Deaconess Medical Center in Boston, MA. During fellowship, Dr. Kaye earned a Masters in Public Health from the Harvard School of Public Health. Dr. Kaye has authored over 300 peer-reviewed articles and 20 book chapters and has presented original research at national and international conferences. Dr. Kaye is Past President of the Society for Health Epidemiology of America (SHEA). He is a recognized expert in healthcare epidemiology and antimicrobial resistance and has been invited to speak on these topics at venues throughout the world.

About Tebipenem HBr
Tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994) is Spero’s novel investigational oral formulation of tebipenem pivoxil, a carbapenem antibiotic of the β-lactam class marketed by Meiji Seika Pharma Co. Ltd. (Meiji) in Japan as Orapenem since 2009 for pediatric infections limited to pneumonia, otitis media and sinusitis. Carbapenems are an important subclass of antibiotics because they have been observed to be safe and effective in the treatment of drug-resistant Gram-negative bacterial infections. Tebipenem HBr is being developed for the treatment of complicated urinary tract infections, including acute pyelonephritis. The Company expects that the favorable ADAPT-PO clinical trial results, once finalized, will support completion of a New Drug Application submission to the U.S. Food and Drug Administration (FDA) for tebipenem HBr in the second quarter of 2021. If approved, tebipenem HBr would be the first oral carbapenem antimicrobial to receive marketing approval in the United States. Tebipenem HBr has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the FDA for the treatment of cUTI and AP.